GENEVA, 5 September 2025—UNAIDS welcomes the announcement by the US State Department that the President’s Emergency Plan for AIDS Relief (PEPFAR) will be supporting an initiative by the Global Fund to Fight AIDS, TB and Malaria to provide lenacapavir to up to 2 million people in countries with high burdens of HIV.

Lenacapavir, an American-based innovation, is one of the most promising new HIV prevention tools that has emerged in the HIV response, offering protection against HIV with just twice-yearly injections. The breakthrough medicine will save thousands of lives if made widely available for all people and populations at risk of HIV including young women and adolescent girls as well as sex workers, people who inject drugs, and men who have sex with men in high burden countries and geographies.

"This deal offers hope that many more people around the world who are at risk of HIV will have access to this revolutionary HIV medicine. More global work will be needed to increase scale and rapidly make lenacapavir available, affordable and accessible in all low and middle-income countries. But at this critical moment, the United States’ backing of this breakthrough medicine is an important signal to the world that by investing in the HIV response we can stop new infections,” said Winnie Byanyima, Executive Director of UNAIDS.

An initial roll-out of 2 million is an important start toward a broader ambition and i t is important that lenacapavir be available to all people in need, not only to some. UNAIDS estimates that 20 million people will need to be reached with antiretroviral-based prevention such as lenacapavir as part of efforts to achieve the 2030 global HIV prevention targets. UNAIDS also estimates that for every US$ 1 invested in HIV prevention, US$ 7 will be saved in treatment and care costs later.

The price for lenacapavir in France, Norway, Spain and the United States in late 2024 exceeded US$ 28 000 per person per year. For this initiative, manufacturer Gilead has pledged to supply the medicine at no profit. Research published earlier this year showed that lenacapavir can be made and sold for just US$ 40 per person per year, falling to US$ 25 with sufficient scale.

To successfully expand access to lenacapavir, community engagement will be essential. To advance progress in the roll-out, populations most impacted by HIV must play a central role in its delivery and people most at risk of HIV must have access.

UNAIDS will continue to support countries and partners in driving the response to HIV forward to ensure that everyone, everywhere has access to the HIV services they need and that AIDS is ended as a public health threat by 2030.

UNAIDS

The Joint United Nations Programme on HIV/AIDS (UNAIDS) leads and inspires the world to achieve its shared vision of zero new HIV infections, zero discrimination and zero AIDS-related deaths. UNAIDS unites the efforts of 11 UN organizations—UNHCR, UNICEF, WFP, UNDP, UNFPA, UNODC, UN Women, ILO, UNESCO, WHO and the World Bank—and works closely with global and national partners towards ending the AIDS epidemic by 2030 as part of the Sustainable Development Goals. Learn more at unaids.org and connect with us on Facebook, Twitter, Instagram and YouTube.